Suchergebnisse - "Pinato, David J"

PubPharm (285)

131

Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma

enthalten in: The lancet. Gastroenterology & hepatology | 2021

von Pinato, D. | Valeri, N. | Muhammed, A. | +1

CommentOn: Lancet Gastroenterol Hepatol. 2021 Jul;6(7):559-568. - PMID 33971141

132

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab

enthalten in: Journal for immunotherapy of cancer | 2021

von Alexander, J. | Ibraheim, H. | Sheth, B. | +20

133

Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis

enthalten in: Journal of hepatology | 2021

von Gudd, C. | Au, L. | Triantafyllou, E. | +17

134

Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer : a European study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Pinato, D. | Scotti, L. | Gennari, A. | +67

CommentIn: Lancet Oncol. 2021 Jun;22(6):755. - PMID 33894836

135

PD-1/PD-L1 checkpoint inhibitors during late stages of life : an ad-hoc analysis from a large multicenter cohort

enthalten in: Journal of translational medicine | 2021

von Santini, D. | Zeppola, T. | Russano, M. | +45

136

PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

enthalten in: Journal of translational medicine | 2021

von Santini, D. | Zeppola, T. | Russano, M. | +45

137

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

enthalten in: JHEP reports : innovation in hepatology | 2021

von Muñoz-Martínez, S. | Sapena, V. | Forner, A. | +82

138

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Buti, S. | Bersanelli, M. | Perrone, F. | +58

CommentIn: Eur J Cancer. 2021 Sep;155:313-314. - PMID 34373189

139

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma : A Network Meta-Analysis

enthalten in: Liver cancer | 2021

von Vogel, A. | Rimassa, L. | Sun, H. | +10

140

A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors

enthalten in: European urology oncology | 2021

von Khaki, A. | Li, A. | Diamantopoulos, L. | +44